Purpose

This registry will collect information about patients with treatment-resistant depression (TRD) who are currently in a major depressive episode. For the purposes of this study, TRD is defined as an ongoing depression lasting at least 2 years or that has recurred at least 3 times, to include the current episode, during the patient's lifetime AND has not adequately responded to 4 or more adequate antidepressive treatments. The registry will follow the clinical course and outcomes for patients with TRD who are treated with and without adjunctive (used along with other treatments for depression) vagus nerve stimulation (VNS) therapy.

Type of Study: Clinical Trial
Setting of Study: outpatient
Clinical Trials.gov number: NCT00320372
Providing Clinical Treatment?: No
No Cost Treatment?: No

Study Activities

Filling Out Forms
Provides Payment: Reimbursement for transportation
Provides Payment: Compensation for study related procedures

Eligibility

Ages Eligible for Study: 18 Years - 90 Years
Genders Eligible for Study: Both
This study is recruiting Healthy Volunteers.

Criteria

Inclusion Criteria:
* Patient diagnosed with a current major depressive episode according to DSM-IV-TR criteria.
* Patient has been in the current depressive episode for 2 years or longer, or has had at least 3 lifetime episodes including the current MDE.
* Patient has had an inadequate response to 4 or more adequate antidepressive treatments.
* The patient has a CGI severity of illness score of moderately ill (score of 4) or greater.
* The patient must be able to provide informed consent and complete all forms.
* The patient is 18 years of age or older.

Links
More information about the Treatment Resistant Depression Registry

Location: Division of Brain Stimulation and Therapeutic Modulation Brain Behavior Clinic Department of Neuroscience New York State Psychiatric Institute 1051 Riverside Drive, Unit 21 New York, NY 10032
Clinic: Novel Treatments for Depression Service
Division: Other

Study chairs or principal investigators:
Sarah Hollingsworth Lisanby MD, Principal Investigator

Co-investigators:
Peter Bulow,
Antonio Mantovan,
Alexandra Sporn,
Arielle Stanford,
Jonathan Stewart